Biotia Raises $9M in Funding

Biotia, a clinical metagenomics company based in New York City that provides AI-powered infectious disease diagnostic services, has raised $9 million in new financing. The capital will be used to scale the company's diagnostic laboratory, expand its test menu into women's health and orthopedic diagnostics, and pursue new reimbursement and commercialization initiatives.

Investors

Participating investors include Convergent Ventures, DigitalDx Ventures, Cloquet Capital Partners, Continuum Health Ventures, I-Lab Angels, EGB Capital, Leawood Venture Capital, Red Bear Angels, Red Bear Ventures, Tim Barry, and Dr. Clive Fields.

Biotia Use of Funds

Biotia plans to use the new capital to increase the capacity of its CLIA-certified laboratory in New York City, develop new diagnostic tests targeting women's health and orthopedic markets, and further the commercial adoption of its precision infectious disease testing platform.

About Biotia

Founded as a spinout from the Jacobs Technion-Cornell Institute at Cornell Tech, Biotia is led by cofounders Niamh O'Hara and Chris Mason. The company mission centers on providing advanced diagnostics for patients with chronic and complex infections using a combination of pathogen genomics and artificial intelligence to improve treatment outcomes.

Funding Details

Company Website: https://biotia.io

Company: Biotia
Raised: $9M
Funding Date: October 1, 2026
Additional Investors: Convergent Ventures, DigitalDx Ventures, Cloquet Capital Partners, Continuum Health Ventures, I-Lab Angels, EGB Capital, Leawood Venture Capital, Red Bear Angels, Red Bear Ventures, Tim Barry, Dr. Clive Fields
Company Website: https://www.biotia.io
Software Category: Healthcare Diagnostics
Source: https://www.citybiz.co/article/912462/biotia-raises-9-million-to-scale-infectious-disease-diagnostics/